Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin

Enfortumab vedotin (EV) is an antibody–drug conjugate with humanized anti-Nectin-4 antibody linked with a microtubule-disrupting agent called monomethyl auristatin E. Nectin-4 is a cellular adhesion protein that is overexpressed in urothelial cancer. EV was approved in December 2019 for patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Rohit K, Skelton, William Paul, Zhang, Jingsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494003/
https://www.ncbi.nlm.nih.gov/pubmed/32982431
http://dx.doi.org/10.2147/CMAR.S224223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494003/
https://www.ncbi.nlm.nih.gov/pubmed/32982431
http://dx.doi.org/10.2147/CMAR.S224223

Ejemplares similares